Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPANRAY vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Serotonin-dopamine activity modulator; partial agonist at 5-HT1A and D2 receptors, antagonist at 5-HT2A receptors.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
FDA: Adjunctive treatment of schizophrenia in adults.,Off-label: Bipolar I disorder (maintenance), major depressive disorder (adjunctive), Tourette syndrome, obsessive-compulsive disorder, post-traumatic stress disorder, autism-associated irritability.
Hypertension
1.5 mg orally once daily at bedtime, titrated up to a maximum of 3 mg once daily.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal elimination half-life is approximately 62 hours following oral administration, allowing for once-daily dosing.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Primarily metabolized by CYP3A4 and CYP2D6; minor pathways include CYP1A2 and CYP2C19.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily hepatic metabolism via CYP1A2 and CYP3A4, with 18% excreted unchanged in urine and 26% in feces as metabolites.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
99.5% bound to albumin and alpha-1-acid glycoprotein.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Apparent Vd is 4.0 L/kg, indicating extensive tissue distribution beyond plasma volume.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral bioavailability is 30–40% due to first-pass metabolism.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use is not recommended due to lack of data.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh Class A: No dosage adjustment. Child-Pugh Class B: Reduce dose to 1 mg once daily, may increase to 1.5 mg based on tolerability. Child-Pugh Class C: Use is not recommended.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not approved for pediatric patients below 18 years of age; no specific dosing guidelines available.
Not established; avoid use in children.
Elderly patients may be more sensitive to sedative and orthostatic hypotensive effects. Initiate at 1 mg once daily, titrate cautiously. Maximum dose 1.5 mg once daily for patients >65 years.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SERPANRAY is not approved for the treatment of dementia-related psychosis.
None
Cerebrovascular adverse events in elderly dementia patients; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes (hyperglycemia, dyslipidemia, weight gain); hyperprolactinemia; orthostatic hypotension; leukopenia/neutropenia/agranulocytosis; seizures; body temperature dysregulation; dysphagia; falls; cognitive and motor impairment; increased mortality in elderly with dementia.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hypersensitivity to SERPANRAY or any of its components; concomitant use with strong CYP3A4 inducers or inhibitors (due to potential for significant drug interactions); history of severe allergic reactions (e.g., anaphylaxis, angioedema) to SERPANRAY.
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Take with food to enhance absorption. High-fat meals increase lumateperone exposure. Avoid grapefruit juice as it may increase drug levels.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
First trimester: No adequate human data; animal studies not available. Risk cannot be excluded. Second/third trimester: No data; consider risks versus benefits. Pregnancy category N (not classified by FDA due to lack of data).
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio unknown. Caution recommended; consider alternative agents.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
No pharmacokinetic studies in pregnancy; dose adjustments not established. Use lowest effective dose if required. Monitor for clinical response and adverse effects.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
SERPANRAY (lumateperone) is an atypical antipsychotic with a unique receptor binding profile (5-HT2A antagonist, D2 antagonist, and SERT inhibitor). It is indicated for schizophrenia and bipolar depression. Dosing is fixed at 42 mg once daily with food. No dose titration required. Common side effects include somnolence, sedation, and dry mouth. Monitor for metabolic changes, extrapyramidal symptoms, and tardive dyskinesia. Avoid use in hepatic impairment (Child-Pugh B or C).
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take SERPANRAY exactly as prescribed once daily with food.,Do not stop taking this medicine without talking to your doctor.,This medicine may cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from a sitting or lying position to minimize dizziness.,Inform your doctor immediately if you experience muscle stiffness, fever, confusion, or uneven heartbeat.,Avoid alcohol while taking SERPANRAY.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPANRAY vs ALDORIL 25, answered by our medical review team.
SERPANRAY is a Antihypertensive that works by Serotonin-dopamine activity modulator; partial agonist at 5-HT1A and D2 receptors, antagonist at 5-HT2A receptors.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPANRAY and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPANRAY is: 1.5 mg orally once daily at bedtime, titrated up to a maximum of 3 mg once daily.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPANRAY and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPANRAY is classified as Category C. First trimester: No adequate human data; animal studies not available. Risk cannot be excluded. Second/third trimester: No data; consider risks versus benefits. Pregnancy category . ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.